Quantitative measurements of bone remodeling using 99mTc- methylene diphosphonate bone scans and blood sampling

Journal of Nuclear Medicine

Volumn 49, Issue 3, 2008, Pages 375-382

  Moore, Amelia E B ^a,b   Blake, Glen M ^a   Fogelman, Ignac ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

99mTc methylene diphosphonate; Bone plasma clearance; Bone remodeling

Indexed keywords

EDETATE CHROMIUM CR 51; MEDRONATE TECHNETIUM TC 99M;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE REMODELING; BONE SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTERMETHOD COMPARISON; KIDNEY CLEARANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AGED; BONE REMODELING; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; METABOLIC CLEARANCE RATE; OSTEOPOROSIS, POSTMENOPAUSAL; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M MEDRONATE;

EID: 40449094601     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.048595     Document Type: Article

References (31)

1. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone density. N Engl J Med. 2002;346:653-661.
2. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056.
3. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-468.
4. Greenspan SL, Bone HG, Ettinger MD, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomised trial. Ann Intern Med. 2007;146:326-339.
5. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
6. Recker RR, Barger-Lux MJ. Bone biopsy and histomorphometry in clinical practise. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 5th ed. Washington, D.C.: The American Society for Bone and Mineral Research; 2003:213-219.
7. Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res. 2004;19:1628-1633.
8. Khosla S, Kleerekoper M. Biochemical markers of bone turnover. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 5th ed. Washington, D.C.: The American Society for Bone and Mineral Research; 2003:166-172.
9. Seibel MJ, Eastell R, Gundberg CM, Hannon R, Pols HAP. Biochemical markers of bone metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. San Diego, CA: Academic Press; 2002:1543-1571.
10. Garnero P, Weichung JS, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
11. Beck-Jensen JE, Kollerup G, Sorensen HA, et al. A single measurement of biochemical markers of bone turnover has limited utility in the individual person. Scand J Clin Lab Invest. 1997;57:351-359.
12. Looker AC, Bauer DC, Chesnut CH, et al. Clinical use of biochemical markers of bone remodelling: current status and future directions. Osteoporos Int. 2000;11:467-480.
13. 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28-49.
14. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate: a superior agent for skeletal imaging - Comparison with other technetium complexes. J Nucl Med. 1975;16:744-755.
15. 18F-Fluoride for bone imaging. Semin Nucl Med. 1972;2:31-37.
16. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole-body retention of Tc-99m disphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270-275.
17. D'Addabbo A, Rubini G, Mele M, et al. A new method of assessing Tc-99m-MDP bone uptake from a bone scan image: quantitative measurement of radioactivity in global skeletal region of interest. Nucl Med Commun. 1992;13:55-60.
18. Brenner W, Bohuslavizki KH, Sieweke N, Tinnemeyer S, Clausen M, Henze E. Quantification of diphoshonate uptake based on conventional bone scanning. Eur J Nucl Med. 1997;24:1284-1290.
19. Scillitani A, Dicembrino F, Chiodini I, et al. Global skeletal uptake of Tc-99m-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover. Osteoporos Int. 2002;13:829-834.
20. 99mTc-MDP. J Nucl Med. 2002;43:338-345.
21. 99mTc-methylene diphosphonate skeletal plasma clearance. J Nucl Med. 2006;47:581-586.
22. Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun. 2004;25:759-769.
23. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
24. Peters AM. Graphical analysis of dynamic data: the Patlak-Rutland plot. Nucl Med Commun. 1994;15:669-672.
25. 51Cr-EDTA overestimate true renal clearance by 10 percent. Eur J Nucl Med. 2003;30:4-8.
26. WHO. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis: Technical Report Series 843. Geneva, Switzerland: World Health Organization; 1994.
27. 99mTc-MDP. J Nucl Med. 2003;44:891-897.
28. Hyldstrup L, McNair P, Ring P, Henriksen O. Studies on diphosphonate kinetics. Part I. Evaluation of plasma elimination curves during 24 h. Eur J Nucl Med. 1987;12:581-584.
29. Hyldstrup L, McNair P, Ring P, Henriksen O. Studies on diphosphonate kinetics. Part II. Whole body bone uptake rate during constant infusion: a refined index of bone metabolism. Eur J Nucl Med. 1987;12:585-588.
30. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
31. Blake GM, Herd RJM, Patel R, Fogelman I. The effect of weight change on total body dual energy x-ray absorptiometry: results from a clinical trial. Osteoporos Int. 2000;11:832-839.